Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats

Metabolism: Clinical and Experimental

Volumn 45, Issue 9, 1996, Pages 1168-1173

  Shimabukuro, Michio ^a   Higa, Satoshi ^a   Shinzato, Tatsushi ^a   Nagamine, Fumio ^a   Komiya, Ichiro ^a   Takasu, Nobuyuki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOZOCIN; TROGLITAZONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL NUCLEUS MEMBRANE; CELL VACUOLE; CONTROLLED STUDY; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; HEART RATE; HEART WORK; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOINSULINEMIA; INTRAVENOUS DRUG ADMINISTRATION; ISOLATED HEART; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SARCOMERE; STREPTOZOCIN DIABETES;

EID: 0029774572     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90018-9     Document Type: Article

References (34)

1. Penpargkul S, Schaible T, Tipintsol T, et al: The effect of diabetes on performance and metabolism of rat hearts. Circ Res 47:911-921, 1981
2. Fein FS, Strobeck JE, Malhotra A, et al: Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 49:1251-1261, 1981
3. Jackson CV, McGrath GM, Tahiliani AG, et al: A functional and ultrastructural analysis of experimental diabetic rat myocardium. Manifestation of a cardiomyopathy. Diabetes 34:876-883, 1985
4. Thompson ED: Structural manifestations of diabetic cardiomyopathy in the rat and reversal by insulin treatment. Am J Anat 182:270-282, 1988
5. Rodrigues B, McNeill JH: The diabetic heart: Metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 26:913-922, 1992
6. Makino N, Dhalla KS, Elimban V, et al: Sarcolemmal calcium transport in streptozotocin-induced diabetic cardiomyopathy in rats. Am J Physiol 253:E202-E207, 1987
7. Bouchard RA, Bose D: Influence of experimental diabetes on sarcoplasmic reticulum function in rat ventricular muscle. Am J Physiol 260:H341-H354, 1991
8. Pierce GN, Dhalla-NS: Mitochondrial abnormalities in diabetic cardiomyopathy. Can J Cardiol 1:48-54, 1985
9. Dillmann WH: Diabetes mellitus induces changes in cardiac myosin of the rat. Diabetes 29:579-582, 1980
10. Tada H, Oida K, Kutsumi Y, et al: Effects of probucol on impaired cardiac performance and lipid metabolism in streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol 20:179-186, 1992
11. Black SC, Katz S, McNeill JH: Cardiac performance and plasma lipids of ω-3 fatty acid-treated streptozotocin-induced diabetic rats. Diabetes 38:969-974, 1988
12. Ramanadham S, Mongold JJ, Brownsey RW, et al: Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am J Physiol 257:H904-H911, 1989
13. Mozaffari MS, Allo S, Schaffer SW: The effect of sulfonylurea therapy on defective calcium movement associated with diabetic cardiomyopathy. Can J Physiol Pharmacol 67:1481-1486, 1989
14. Shimabukuro M, Nagamine F, Murakami K, et al: Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats. Gen Pharmacol 25:697-704, 1994
15. Afzal N, Ganguly PK, Dhalla KS, et al: Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37:936-942, 1988
16. Shimabukuro M, Shinzato T, Higa S, et al: Impaired mechanical response to calcium of diabetic rat hearts: Reversal by nifedipine treatment. J Cardiovasc Pharmacol 26:495-502, 1995
17. Higa S, Shimabukuro M, Shinzato T, et al: Nifedipine reduces calcium overload in isolated reperfused hearts of diabetic rats. Gen Pharmacol 26:1679-1686, 1995
18. Fujiwara T, Yoshioka S, Yoshioka T, et al: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
19. Lee MK, Miles PD, Khoursheed M, et al: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439, 1994
20. Iwamoto Y, Kuzuya T, Matsuda A, et al: Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
21. Nolan JJ, Ludvik B, Beerdsen P, et al: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
22. Ciaraldi TP, Gilmore A, Olefsky JM, et al: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
23. Eckel J, Bähr M, Spelleken M, et al: Multiple direct effects of troglitazone on isolated ventricular cardiomyocytes. Diabetes 44:71A, 1995 (suppl 1, abstr)
24. Neely JR, Liebermeister H. Battersby EJ, et al: Effect of pressure development on oxygen consumption by isolated rat heart. Am J Physiol 212:804-814, 1967
25. Zhang F, Sowers JR, Ram JL, et al: Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24:170-175, 1994
26. Pershadsingh HA, Szollosi J, Benson S, et al: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 21:1020-1023, 1993
27. 2+ signaling in rat pancreatic islets. Biomed Res 16:345-351, 1995
28. 2+-channels during the development of diabetic cardiomyopathy. Mol Cell Biochem 109:173-179, 1992
29. Kashiwagi A, Nishio Y, Ogawa T, et al: Increases in voltage-sensitive calcium channel of cardiac and skeletal muscle in streptozotocin-induced diabetic rats, in Nagano M, Mochizuki S, Dhalla NS (eds): Cardiovascular Disease in Diabetes. Boston, MA, Kluwer, 1992, pp 173-182
30. Dandona P, Khurana U, Aljada A, et al: Troglitazone as an antioxidant. Diabetes 44:57A, 1995 (suppl 1, abstr)
31. Collier A, Ailson R, Bradley H, et al: Free radical damage in type II diabetes. Diabetic Med 7:27-30, 1990
32. Hess ML, Okabe E, Kontos HA: Proton and free oxygen radical interaction with the calcium transport system on cardiac sarcoplasmic reticulum. J Moll Cell Cardiol 13:767-772, 1981
33. 2+ pump activity by oxygen free radicals. Am J Physiol 256:H368-H374, 1989
34. Petty MA, Lukovic L, Grisar JM, et al: Myocardial protection by a cardioselective free radical scavenger. Eur J Pharmacol 255:215-222, 1994